<DOC>
	<DOCNO>NCT00920907</DOCNO>
	<brief_summary>The purpose clinical research study compare pharmacokinetics ipilimumab manufacture two different process</brief_summary>
	<brief_title>Comparison Ipilimumab Manufactured 2 Different Processes Participants With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologic diagnosis malignant melanoma Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Measurable/evaluable disease per modify World Health Organization ( mWHO ) criterion Active Brain Metastasis Primary ocular mucosal melanoma Prior Autoimmune disease Inadequate hematologic , hepatic renal function Use immunosuppressants Prior treatment CD137 agonist cytotoxic T lymphocyte antigen 4 ( CTLA4 ) inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>